2025 Mid-Year Myeloma Review with Paul Richardson, MD, Dana Farber Cancer Institute
Spotify%20--%3e%3csvg%20version='1.1'%20id='Livello_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20width='300px'%20height='300px'%20viewBox='0%200%20300%20300'%20enable-background='new%200%200%20300%20300'%20xml:space='preserve'%3e%3cg%20id='XMLID_632_'%3e%3clinearGradient%20id='XMLID_2_'%20gradientUnits='userSpaceOnUse'%20x1='150'%20y1='0'%20x2='150'%20y2='300'%3e%3cstop%20offset='0'%20style='stop-color:%23F452FF'/%3e%3cstop%20offset='1'%20style='stop-color:%23832BC1'/%3e%3c/linearGradient%3e%3cpath%20id='XMLID_662_'%20fill-rule='evenodd'%20clip-rule='evenodd'%20fill='url(%23XMLID_2_)'%20d='M294.1,260c-2.9,7.4-9.6,17.8-19.2,25.2%20c-5.5,4.2-12.1,8.3-21.1,11c-9.6,2.9-21.5,3.8-36.3,3.8h-135c-14.8,0-26.6-1-36.3-3.8c-9-2.7-15.6-6.7-21.1-11%20c-9.5-7.3-16.3-17.8-19.2-25.2C0.1,245.1,0,228.2,0,217.5l0,0v-135l0,0C0,71.8,0.1,54.9,5.9,40c2.9-7.4,9.6-17.8,19.2-25.2%20c5.5-4.2,12.1-8.3,21.1-11C55.9,1,67.7,0,82.5,0l0,0h135l0,0c14.8,0,26.6,1,36.3,3.8c9,2.7,15.6,6.7,21.1,11%20c9.5,7.3,16.3,17.8,19.2,25.2c5.9,14.9,5.9,31.9,5.9,42.5v135C300,228.2,299.9,245.1,294.1,260z'/%3e%3cg%3e%3cpath%20id='XMLID_657_'%20fill='%23FFFFFF'%20d='M175.7,181.1c-0.4-3.6-1.6-6.2-4-8.6c-4.5-4.7-12.4-7.8-21.7-7.8c-9.3,0-17.2,3-21.7,7.8%20c-2.3,2.5-3.6,5-4,8.6c-0.8,7-0.3,13,0.5,22.7c0.8,9.2,2.3,21.5,4.2,33.9c1.4,8.9,2.5,13.7,3.5,17.1c1.7,5.6,7.8,10.4,17.5,10.4%20c9.7,0,15.9-4.9,17.5-10.4c1-3.4,2.1-8.2,3.5-17.1c1.9-12.5,3.4-24.7,4.2-33.9C176.1,194.1,176.5,188.1,175.7,181.1z'/%3e%3cpath%20id='XMLID_655_'%20fill='%23FFFFFF'%20d='M174.6,130.1c0,13.6-11,24.6-24.6,24.6s-24.6-11-24.6-24.6c0-13.6,11-24.6,24.6-24.6%20S174.6,116.6,174.6,130.1z'/%3e%3cpath%20id='XMLID_653_'%20fill='%23FFFFFF'%20d='M149.7,33.2C92.3,33.4,45.3,80,44.5,137.4c-0.6,46.5,29.1,86.3,70.6,100.9%20c1,0.4,2-0.5,1.9-1.5c-0.5-3.6-1.1-7.2-1.5-10.8c-0.2-1.3-1-2.3-2.1-2.9c-32.8-14.3-55.7-47.2-55.3-85.3%20c0.5-50,41.3-90.7,91.2-91.1c51.1-0.4,92.8,41,92.8,92c0,37.7-22.8,70.1-55.3,84.4c-1.2,0.5-2,1.6-2.1,2.9%20c-0.5,3.6-1,7.2-1.5,10.8c-0.2,1.1,0.9,1.9,1.9,1.5c41.1-14.4,70.6-53.6,70.6-99.6C255.5,80.5,208,33.1,149.7,33.2z'/%3e%3cpath%20id='XMLID_651_'%20fill='%23FFFFFF'%20d='M147.3,68.2c-37.4,1.4-67.4,32.3-67.9,69.7c-0.3,24.6,12,46.4,30.9,59.3%20c0.9,0.6,2.2-0.1,2.2-1.2c-0.3-4.3-0.3-8.1-0.1-12.1c0.1-1.3-0.4-2.5-1.4-3.4c-11.5-10.8-18.5-26.2-18.1-43.2%20c0.8-30,24.9-54.4,54.9-55.6c32.6-1.3,59.4,24.9,59.4,57.1c0,16.4-7,31.2-18.1,41.7c-0.9,0.9-1.4,2.1-1.4,3.4%20c0.2,3.9,0.1,7.7-0.1,12c-0.1,1.1,1.2,1.9,2.2,1.2c18.6-12.7,30.9-34.2,30.9-58.4C220.8,98.9,187.5,66.6,147.3,68.2z'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Apple Podcasts
YoutubeThe world of immunotherapy in multiple myeloma is exploding - with new treatments being FDA-approved and others working their way through the FDA approval process. In this show, Dr. Paul Richardson focuses on the innovation in immunotherapy that we've seen in the first half of 2025. This includes a discussion about CAR T, bispecific and trispecific antibodies, and a deeper dive on a new class of drugs in myeloma called Antibody Drug Conjugates, with a drug called belantamab mafodotin going through the FDA review process, with a hopeful approval in October of this year.
Jenny Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Paul Richardson, MD
Paul Richardson, MD, is the RJ Corman Professor of Medicine at the Harvard Medical School, Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, of the Dana-Farber Cancer Institute (DFCI) in Boston. Dr. Richardson received his medical degree from the Medical College of St. Bartholomew’s Hospital in London, UK. His postdoctoral training included internship in the Departments of Medicine & Surgery at St. Bartholomew’s Hospital; residency in the Department of Medicine at Newcastle University School of Medicine; appointment as Chief Resident in Medical Oncology at the Royal Marsden Hospital in London and Surrey; and additional residency training at the Beth Israel Hospital in Boston, USA. He completed fellowships in hematology/oncology and medical oncology at Tufts University School of Medicine, Baystate Medical Center, and Harvard Medical School, Dana-Farber Cancer Institute before coming on staff at DFCI in 1994. Dr. Richardson currently holds leadership positions in several professional bodies and serves on the Editorial Board of the Journal of Clinical Oncology, the Journal of Oncology, The Oncologist, Clinical Cancer Research, and the British Journal of Hematology. He is the prior Chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core, a position he held for 5 years as a founding member and as part of a rotating tenure, and for which he continues to serve on the Steering Committee and Project Review Committee. He now chairs the newly formed Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALGB). His honors include several Massachusetts General Hospital, Brigham and Women’s Hospital, and Dana-Farber Partners in Excellence Awards; The Brigham and Women’s Hospital Teaching Scholars Award; The Tisch Outstanding Achievement Award for Clinical Research; and the Dana-Farber Cancer Institute’s George Canellos Award for Excellence in Clinical Research and Patient Care. For his contributions in hematology and oncology, and in particular myeloma, he was awarded an honorary Fellowship of the Royal College of Physicians (FRCP) in 2009, and he was also more recently a co-recipient of the prestigious Warren Alpert Prize in 2012, the Ernest Beutler Prize at ASH 2015, and the Robert A Kyle Lifetime Achievement Award in 2017.
